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Abstract
Type 2 diabetes mellitus (T2DM) is highly prevalent in the general population and especially in patients with heart failure (HF). It
is not only a risk factor for incident HF, but is also associated with worse outcomes in prevalent HF. Therefore,
antihyperglycaemic management in patients at risk of or with established HF is of importance to reduce morbidity/mortality.
Following revision of the drug approval process in 2008 by the Food and Drug Administration and European Medicines Agency,
several cardiovascular outcome trials on antihyperglycaemic drugs have recently investigated HF endpoints. Signals of harm in
terms of increased risk of HF have been identified for thiazolidinediones and the dipeptidyl peptidase 4 inhibitor saxagliptin, and
therefore, these drugs are not currently recommended in HF. Sulfonylureas also have an unfavourable safety profile and should
be avoided in patients at increased risk of/with HF. Observational studies have assessed the use of metformin in patients with
HF, showing potential safety and potential survival/morbidity benefits. Overall use of glucagon-like peptide 1 receptor agonists
has not been linked with any clear benefit in terms of HF outcomes. Sodium–glucose cotransporter protein 2 inhibitors (SGLT2i)
have consistently shown to reduce risk of HF-related outcomes in T2DM with and without HF and are thus currently recom-
mended to lower risk of HF hospitalization in T2DM. Recent findings from the DAPA-HF trial support the use of dapagliflozin
in patients with HF with reduced ejection fraction and, should ongoing trials with empagliflozin, sotagliflozin, and canagliflozin
prove efficacy, will pave the way for SGLT2i as HF treatment regardless of T2DM.
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Introduction
Heart failure (HF) and type II diabetes mellitus (T2DM) are
highly prevalent and inflict a considerable financial burden
on health care systems.1,2 They often coexist, with 40% of pa-
tients hospitalized for HF also having diabetes and 12% of pa-
tients with diabetes suffering also from HF.3,4 Patients with
concomitant HF and T2DM report worse prognosis as com-
pared with those suffering from only one of these diseases.5,6
In 2008, the Food and Drug Administration and the Euro-
pean Medicines Agency revised the approval processes for
glucose-lowering therapies, requiring cardiovascular (CV) out-
come trials to be completed either before or after approval
for any new antidiabetic medication. This decision followed
the publication of a meta-analysis showing that rosiglitazone,
although significantly lowering glycated haemoglobin, in-
creased the risk of myocardial infarction, which led to ques-
tions regarding the use of glycaemic control as efficacy and
registration outcome in randomized controlled trials (RCTs)
evaluating the efficacy/safety of glucose-lowering drugs.7 Al-
though regulatory agencies focused on the risk of
macrovascular events, rosiglitazone also significantly
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increased the risk of HF. Given the important interaction be-
tween T2DM and HF, worsening/hospitalization for HF has
been used as an important secondary endpoint in all the re-
cent RCTs focusing on T2DM treatments.
The aim of this review is to summarize and structure the
current evidence on the interplay between glucose-lowering
drugs and HF.
Non-insulin antihyperglycaemic
medications inducing harm in heart
failure: thiazolidinediones
Thiazolidinediones (TZDs) effectively lower glucose levels by
increasing insulin sensitivity in peripheral tissues.8 In the
PROACTIVE RCT, enrolling more than 5000 patients with
T2DM and established macrovascular disease, pioglitazone
vs. placebo reduced by 10% the risk of the primary outcome,
which included any death, non-fatal myocardial infarction,
stroke, acute coronary syndrome, coronary or leg arteries
revascularization, or amputation above the ankle,9 but also
increased risk of HF hospitalization.9 Similarly, in the RE-
CORD trial, a 2.6-fold increased risk of HF requiring hospital-
ization or leading to death was observed in patients
randomized to rosiglitazone on top of metformin or sulfonyl-
urea monotherapy vs. a combination of metformin and sul-
fonylurea, whereas there was no difference in risk of CV
death, myocardial infarction, and stroke.10 Two
meta-analyses confirmed these findings, suggesting a class
effect for TZD on HF event risk,11,12 which may be explained
by renal sodium retention triggered by the peroxisome
proliferator-activated receptor gamma activation by TZD.13
Therefore, the use of TZD for treatment of T2DM in patients
with HF is not recommended in the current European and
American HF guidelines.14,15
Non-insulin antihyperglycaemic
medications inducing potential harm in
heart failure: inhibitors of dipeptidyl
peptidase 4 and sulfonylureas
Inhibitors of dipeptidyl peptidase 4
Inhibitors of dipeptidyl peptidase 4 (DPP4i) increase
pre-prandial and post-prandial levels of GLP1, which pro-
motes insulin secretion and suppresses glucagon secretion,
leading to improved glycaemic control.16
The SAVOR-TIMI 53 trial was the first large-scale RCT test-
ing DPP4i vs. placebo on top of usual care in more than
16 000 patients with T2DM and either history or high risk of
CV disease.17 Although saxagliptin did not affect the primary
major adverse cardiovascular event (MACE) endpoint, it sig-
nificantly increased the risk of HF hospitalization by 27% as
compared with placebo.17 Notably, saxagliptin-associated in-
crease in risk of HF hospitalization was greater in patients
with history or at higher risk of HF (i.e. impaired renal func-
tion, or elevated baseline levels of N-terminal pro-B-type na-
triuretic peptides).18 Although the underlying mechanisms for
these findings are not clear, saxagliptin has been suggested to
directly interact with myocytes and affect intracellular Ca2+
levels, leading to impaired contractility.19 In the EXAMINE
trial, which tested alogliptin vs. placebo in patients with
T2DM hospitalized for acute coronary syndrome, the MACE
outcome was not met, and although the risk of HF was not
significantly increased by the treatment, a higher number of
HF events was observed in patients receiving alogliptin
(3.1%) vs. placebo (2.9%).20,21
The finding of DPP4i increasing the risk of HF hospitaliza-
tion could not be confirmed in other RCTs. Indeed, both the
TECOS trial,22 testing sitagliptin vs. placebo in T2DM patients
with established CV disease, and the CARMELINA trial,23 test-
ing linagliptin vs. placebo in T2DM patients at high risk of CV
and renal diseases, showed no effect of DPP4i on HF-related
endpoints nor on the primary MACE outcome.24,25 Finally, in
the VIVIDD trial, enrolling 254 patients with T2DM and HF
with reduced ejection fraction (HFrEF) (<40%), vildagliptin
(vs. placebo) did not affect ejection fraction (EF) but in-
creased left ventricular volumes.26 The study also showed
that vildagliptin increased, albeit not significantly, CV mortal-
ity. The CAROLINA trial, which randomized 6033 T2DM pa-
tients with or at increased risk of CV disease to linagliptin
vs. the sulfonylurea glimepiride on top of standard care,
showed no increased risk of MACE and of HF-related out-
comes with linagliptin vs. glimepiride over a median
follow-up of more than 6 years.27
An increased risk of HF was thus observed only in the
SAVOR-TIMI 53 with concordant signals in EXAMINE and
VIVVID. However, a possible increase in occurrence of HF hos-
pitalizations cannot be completely ruled out in the studies
with DPP4i reporting a null effect given that HF hospitaliza-
tions had not been prospectively assessed and adjudicated.
The Food and Drug Administration expanded the warning re-
garding cautious use in HF patients to the whole DPP4i class
and consistently amended product labels.
Sulfonylureas
Sulfonylureas facilitate insulin release and hereby lower
blood glucose levels, but clinical use of these drugs is limited
by side effects such as weight gain and a high risk of
hypoglycaemia.28 Although CV safety of sulfonylureas has
been debated for many years, the evidence on this topic is
mostly based on observational data.28 In a meta-analysis of
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observational studies, as well as in a propensity score
matched analysis of the National Veterans Health Administra-
tion databases, use of sulfonylureas was associated with
higher risk of HF as compared with metformin.29,30 However,
in the UKPDS 33 trial, which randomized 3867 patients with
T2DM to intensive vs. conventional blood glucose control
with sulfonylureas or metformin vs. diet, no study treatment
increased risk of CV events, including HF.31 In the ADOPT trial,
randomizing 4360 patients with T2DM to rosiglitazone,
glyburide, or metformin, glyburide was associated with a
lower risk of CV events (including HF) than was rosiglitazone,
and the risk associated with metformin was similar to that
with rosiglitazone.32 Finally, in a recent retrospective cohort
study of 132 737 patients with T2DM, starting sulfonylureas
on top of metformin or no previous antidiabetic treatment
was associated with a higher risk of CV events, and in partic-
ular of HF, compared with initiating DPP4i.33 Conversely, in
the CAROLINA trial, the risk of CV events, including also HF,
did not differ in patients receiving glimepiride vs. DPP4i
linagliptin.27
Overall, the available data regarding the risk of HF with sul-
fonylureas are conflicting, and these agents might be or not
be harmful in patients with or at risk of HF. Therefore, other
antihyperglycaemic treatments with proven safety/efficacy
profile should be preferred to sulfonylureas in T2DM patients
with or at high risk of HF.
Non-insulin antihyperglycaemic
medications with potential neutral
effect in heart failure: glucagon-like
peptide 1 receptor agonists
Glucagon-like peptide 1 (GLP1) increases insulin secretion
and downregulates glucagon in response to food intake, im-
proving glycaemic control.34 GLP1 receptor antagonists
(GLP1-RAs) enhance this effect and reduce appetite, induc-
ing also weight loss.34 Experimental studies in animal
models show that lack of GLP-1R results in impaired left
ventricular contractility and decreased resting heart rate.35
Notably, GLP-1 infusion increases left ventricular contractil-
ity, stroke volume, and cardiac output in animal models of
induced dilated cardiomyopathy.36 All these data, together
with the evidence of a role for GLP-1 on post-ischaemia re-
covery and myocardial viability, have suggested a potential
benefit for GLP-1RA in patients with T2DM and concomitant
HF.37,38
Several CV outcome trials have evaluated efficacy and
safety of GLP1-RA. The ELIXA trial randomized 6068 patients
with T2DM and a recent acute coronary syndrome to
lixisenatide vs. placebo. Lixisenatide did not reduce the pri-
mary outcome of the trial (composite of CV death,
myocardial infarction, stroke, or hospitalization for unstable
angina) or any of the secondary endpoints, including also
HF hospitalization.39 Similarly, the EXSCEL trial, randomizing
14 752 patients with T2DM with or without pre-existing
CV disease, showed that exenatide was not superior to pla-
cebo in terms of MACE risk reduction.40 Although exenatide
reduced the composite endpoint of all-cause mortality and
hospitalization for HF in the overall cohort, this benefit
was attenuated in patients with prevalent HF at baseline.41
In the LEADER, SUSTAIN-6, and HARMONY OUTCOMES tri-
als, the GLP1-RA liraglutide, semaglutide, and albiglutide, re-
spectively, reduced the MACE endpoint as compared with
placebo, but, once again, not the risk of HF
hospitalization.42–44 Finally, PIONEER-6, randomizing 3183
subjects at high CV risk, showed semaglutide being
non-inferior to placebo for risk of MACE and HF hospitaliza-
tion, but decreasing the risk of CV death by 51% and the
risk of all-cause death by 49%.45 Interestingly, in a recent
meta-analysis of all major CV outcome trial on GLP1-RA,
these drugs were reported to slightly reduce the risk of HF
hospitalization.46
Two phase II RCTs have focused on investigating
liraglutide vs. placebo in HF patients with or without con-
comitant T2DM. The FIGHT trial randomized 300 patients
hospitalized for acute HFrEF (<40%).47 The primary outcome
was a global rank score in which all patients, regardless of
treatment assignment, were ranked across three hierarchical
tiers: time to death, time to HF rehospitalization, and
time-averaged proportional change in N-terminal
pro-B-type natriuretic peptide level from baseline to
180 days.47 The LIVE trial randomized 241 patients with clin-
ically stable HFrEF (<45%) and on optimal HF treatment with
or without T2DM.48 The primary endpoint was change in EF
from randomization to end of follow-up.48 Neither FIGHT
nor LIVE met their primary outcome.47,48 Notably, in LIVE,
a significant increase in heart rate as well as in the occur-
rence of serious cardiac and HF-related events was observed
in the liraglutide vs. the placebo arm.48 Albeit the explor-
atory nature and the small number of patients and events,
these results have questioned the use of GLP1-RA in pa-
tients with HF. Finally, the REWIND trial, which has random-
ized 9901 T2DM patients with or at high risk of CV disease
to dulaglutide vs. placebo, also showed a reduction in risk
of the primary MACE outcome but no differences for HF
hospitalization.49
Non-insulin antihyperglycaemic
medications with potential benefit in
heart failure: metformin
Besides classical glucose-lowering mechanisms, that is, reduc-
tion of hepatic gluconeogenesis and increasing peripheral
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insulin sensitivity, metformin has been recently suggested to
act on the intestine by increasing GLP-1 secretion and possi-
bly altering the microbiome.50 Metformin has been the cor-
nerstone of T2DM therapy for decades, which has led to a
deep clinical experience with its use. The cardioprotective
role of metformin has emerged in the UKPDS trials, with
the UKPDS 34 showing a reduction in risk of
diabetes-related endpoints and mortality in overweight pa-
tients with newly diagnosed T2DM receiving metformin vs.
diet.51 In the UKPDS 80 trial, metformin was shown to reduce
the risk of any diabetes-related endpoint, including also HF,
and of myocardial infarction and mortality compared with
diet over a follow-up of 10 years.52 However, a recent
meta-analysis of RCTs could not report any reduction in risk
of HF linked with use of metformin vs. placebo or other
treatments.53
Metformin may be beneficial in patients with HF by en-
hancing glucose uptake in insulin-resistant cardiomyocytes
and attenuating remodelling as suggested by experimental
studies54,55 and by improving myocardial efficiency by re-
ducing myocardial oxygen consumption.56 Importantly, met-
formin use was initially limited to non-HF T2DM patients
due to concerns regarding a potentially increased risk of
lactic acidosis,57 which has been proven to be very low in
clinical practice (<10 cases per 100 000 patient-years).58
Similarly, the glomerular filtration rate label criterion for
metformin has been lowered from ≥60 to ≥30 mL/min in
the past years, as concerns regarding its safety in patients
with moderately reduced kidney function could not be
confirmed.59 The European Society of Cardiology (ESC)
guidelines on HF and the recent ESC guidelines on diabetes
recommend metformin as a treatment option for T2DM pa-
tients with HF (class IIa; level C),14,28 whereas the American
Heart Association/American College of Cardiology guidelines
are more cautious.60 Notably, current evidence on metfor-
min is mainly based on extensive clinical experience, obser-
vational studies and smaller RCTs assessing primarily
glycaemic control, because metformin has not been tested
in CV outcome trials.61 In a nested case–control study en-
rolling around 3500 patients with both HF and T2DM, met-
formin use was significantly associated with improved
survival, as compared with patients not exposed to any an-
tidiabetic drug.62 Similarly, in a propensity score matched
analysis of around 6000 patients with T2DM and concomi-
tant HF, treatment with metformin vs. other antidiabetic
treatments was associated with a 24% improved survival.63
In a propensity score matched analysis of around 130 000
patients with T2DM, those receiving metformin had 32%
lower risk of being hospitalized or dying for HF as com-
pared with patients treated with a sulfonylurea.30 However,
metformin did not improve exercise capacity in a random-
ized trial of 62 HFrEF patients comparing metformin vs. pla-
cebo and had no effect on risk of HF in a meta-analysis of
RCTs.61,64
Non-insulin antihyperglycaemic
medications with benefit in heart
failure: sodium–glucose cotransporter
protein 2 inhibitors
Sodium–glucose cotransporter protein 2 inhibitors (SGLT2i)
block the sodium–glucose cotransporter protein 2 in the
proximal convoluted tube of the kidney. They increase uri-
nary glucose excretion (i.e. glycosuria) but do not increase
the risk of hypoglycaemia (unless paired with insulin or sulfo-
nylurea), as the extent of glucose lowering depends on
starting glucose (and is therefore smaller in patients with
low glucose levels). The glycosuria and concomitant natriure-
sis lead to a decrease in extracellular volume,65 which may
promote a reduction in vascular wall stress, less congestion,
and improved cardiac function.66 By preventing coupled glu-
cose and sodium reabsorption in the proximal tubule, sodium
delivery to the macula densa increases, which leads through
tubulo-glomerular feedback to afferent arteriole
adenosine-induced vasoconstriction and therefore attenua-
tion of chronic hyperfiltration responsible for nephron loss.65
Interestingly, it has been suggested that while conventional
diuretics reduce intravascular volume and thus cause mal-
adaptive neurohormonal activation, SGLT2i may be associ-
ated with greater vascular refill and greater reduction of
interstitial fluid.67 SGLT2i have also metabolic effects on the
heart. By increasing glucagon levels, they may exert a positive
inotropic and chronotropic effect.68 Additionally, by increas-
ing hydroxybutyrate levels, they may foster a shift in myocar-
dial fuel supply from fatty acids and glucose to the more
energy-efficient ketones in the diabetic heart.69 Finally,
SGLT2i foster the inhibition of the sodium–hydrogen ex-
changer in the heart, which has been shown to minimize car-
diomyocyte injury and attenuate the development of cardiac
hypertrophy, remodelling, systolic dysfunction, and fibrosis.70
Both haemodynamic, metabolic, and renal effects induced by
SGLT2i may be particularly beneficial in patients with HF.70
The first landmark trial to evaluate the efficacy and safety
of SGLT2i in T2DM patients was the EMPA-REG
OUTCOME.71 This RCT allocated 7020 individuals with
T2DM and established CV disease to receive empagliflozin
vs. placebo. Over a median follow-up of 3.1 years,
empagliflozin reduced the risk of the primary outcome (i.e.
composite of CV death, myocardial infarction, or stroke)
by 14%, CV death by 38%, all-cause mortality by 32%, and
notably, risk of HF hospitalization by 35%.71 These benefits
were consistent in patients with and without HF at baseline,
as well as in patients at different risk of HF outcomes.72 A
post hoc analysis of the EMPA-REG OUTCOME trial showed
that empagliflozin may reduce the risk of HF hospitalization,
CV, and any death following a first hospitalization for HF,
providing a rationale for studying SGLT2i specifically in the
post-acute HF window.73
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More recently, the CANVAS trial,74 which investigated
canagliflozin vs. placebo in T2DM patients with established
or high risk of CV disease, canagliflozin significantly reduced
the primary MACE endpoint by 24% but not its individual
components.74 Like empagliflozin,72 canagliflozin significantly
reduced the risk of HF hospitalization by 33%.74 Notably, the
observed absolute, but not relative, risk reductions of CV
death or HF hospitalization and of HF hospitalization alone
were greater in patients with vs. without a history of HF.75
Additionally, the CREDENCE trial, which was planned to ran-
domize 6000 patients with T2DM and chronic kidney disease
to either canagliflozin or placebo, was stopped earlier as a
planned interim analysis showed a 30% lower risk of the pri-
mary endpoint (end-stage renal disease/doubling of serum
creatinine/death from renal or CV cause) in the intervention
arm.76 Interestingly, canagliflozin was also shown to reduce
the risk of HF hospitalization by 39%.76 The EMPA-KIDNEY
and the DAPA-CKD trials, which evaluate the effect of
empagliflozin/dapagliflozin in patients with chronic kidney
disease, are currently ongoing and will provide further
evidence.77,78 Of note, DAPA-CKD has recently been stopped
for efficacy, per a press release issued by the manufacturer.79
Recently, the results of the third landmark trial evaluating
efficacy/safety of SGLT2i were published. The DECLARE TIMI
58 trial randomized 17 160 T2DM patients with history or at
high risk of CV disease to dapagliflozin or placebo.
Dapagliflozin did not significantly reduce the risk of MACE,
but led to a 17% significant reduction of risk of CV death or
HF hospitalization, which was mainly driven by a reduction
of HF hospitalization.80 Notably, in a post hoc analysis,
dapagliflozin reduced the risk of HF hospitalization in patients
with HF, regardless of EF, as well in those without HF, but re-
duced the risk of CV and all-cause death only in patients with
HFrEF.81 One more trial on the SGLT2i ertugliflozin vs. pla-
cebo, the VERTIS-CV, is currently ongoing and enrolling pa-
tients with T2DM and established CV disease. It is expected
to enrol 8000 patients, and results are expected in 2020. HF
hospitalization is one of the secondary endpoints considered
in this trial.82
The consistent finding of SGLT2i reducing HF-related hospi-
talizations in patients with/without established HF supports a
potential class effect for these drugs on HF events. These trial
findings, together with an emerging understanding of mecha-
nisms of action of this pharmacological class, have led to the
hypothesis whether SGLT2i may be beneficial in terms of
mortality/morbidity reduction also in HF patients without
T2DM, who were not enrolled in the above-mentioned trials.
Several RCTs are testing this hypothesis, that is, SGLT2i as an
HF treatment, irrespective of coprevalent T2DM. The
DAPA-HF, randomizing 4744 patients with symptomatic HFrEF
(≤40%), with and without T2DM, to dapagliflozin vs. placebo,
was the first and so far only RCT to report.83 Over a median
follow-up of 18.2 months, dapagliflozin reduced the primary
composite outcome of CV death or worsening HF by 26%.83
This effect was consistent for all the individual components
of the composite endpoint as well as across several
pre-specified subgroups, including patients with and without
T2DM at baseline.83 Notably, the benefit in terms of hard out-
comes was paralleled by an improvement in symptoms, phys-
ical function, and quality of life.84 Furthermore, the trial did
not raise any relevant drug-related safety concern regardless
of age, as there was no higher incidence of volume depletion
or serious adverse renal events in the treatment group.84,85
Later in the DEFINE-HF trial, randomizing 263 patients with
HF and EF ≤ 40%, NYHA classes II–III, elevated natriuretic pep-
tides, with and without T2DM, to dapagliflozin 10mg daily vs.
placebo for 12 weeks, patients receiving dapagliflozin were
more likely to experience clinically meaningful improvements
in a dual primary endpoint of HF-related health status or ≥20%
decrease in natriuretic peptide levels, although there was no
significant difference in the mean natriuretic peptide levels
between study groups.86 More recently, the
EMPERIAL-Reduced (EF ≤ 40%) and EMPERIAL-Preserved
(EF > 40%) trials, both randomizing 300 patients with chronic
HF to empagliflozin vs. placebo, could not show an effect on
exercise capacity (change in 6-min walk distance from base-
line to a 12-week follow-up).87 In an RCT enrolling 80 acute
HF patients with and without T2DM, empagliflozin
10 mg/day vs. placebo for 30 days did not significantly im-
prove dyspnoea, diuretic response, natriuretic peptide levels,
and length of hospital stay.88
Upcoming evidence on sodium–glucose
cotransporter protein 2 inhibitors
Several phase III RCTs on SGLT2i are currently ongoing in HF
with both reduced and preserved EF. The DELIVER trial aims
to test the efficacy of dapagliflozin in terms of reduction of
CV death or HF hospitalization/urgent visit in 4700 patients
with symptomatic HF with EF > 40% regardless of T2DM
status.89 The EMPEROR-Preserved trial enrolling patients with
HF with EF > 40% and the EMPEROR-Reduced in HF with
EF ≤ 40% will randomize 5750 and 3600 symptomatic HF pa-
tients regardless of T2DM status, respectively, to
empagliflozin vs. placebo.90,91 Both trials use a different pri-
mary endpoint as compared with DAPA-HF, that is, composite
of CV death and HF hospitalization, excluding urgent visits not
leading to hospitalization. Furthermore, the
EMPEROR-Reduced trial aims to enrol patients with more se-
vere HF as compared with DAPA-HF, as explained by the
higher N-terminal pro-B-type natriuretic peptide cut-off for
patient inclusion.90 Finally, the SOLOIST-WHF trial was esti-
mated to randomize 4000 patients with haemodynamically
stable HF, regardless of EF, and T2DM, following a hospital
admission for worsening HF, to sotagliflozin vs. placebo,92
but was closed out early due to funding and COVID-19
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Table 1 Recent trials of antidiabetic therapies focusing heart failure outcomes
Drug Clinical trial Design Primary outcome HF-related outcome
Thiazolidinediones
Pioglitazone PROACTIVE9 ▪34.5 months, 1:1
randomized,
placebo-controlled trial




non-fatal MI, stroke, ACS,
coronary or leg artery
revascularization,
amputation)
Increased risk of HF
hospitalization
Rosiglitazone RECORD10 ▪5.5 years, 1:1 randomized,
placebo-controlled trial




hospitalization or CV death)
Increased risk of HF
hospitalization or HF death
Inhibitors of dipeptidyl peptidase 4
Saxagliptin SAVOR-TIMI
5317
▪2.1 years, 1:1 randomized,
placebo-controlled trial
▪16 492 patients with T2DM




(composite of CV death, MI,
or ischaemic stroke)
Increased risk of HF
hospitalization, especially in
patients with prevalent HF
or at high risk of HF
Alogliptin EXAMINE20 ▪18 months, 1:1
randomized,
placebo-controlled trial
▪5380 patients with T2DM
and a recent ACS
Non-inferiority for the
primary outcome
(composite of CV death, MI
or ischaemic stroke)
Numerically higher HF event
rate
Sitagliptin TECOS22 ▪3 years, 1:1 randomized,
placebo-controlled trial
▪14 671 patients with T2DM
and established CV disease
Non-inferiority for the
primary outcome
(composite of CV death, MI,
stroke, or hospitalization for
unstable angina)
No effect on HF-related
endpoints
Linagliptin CARMELINA23 ▪2.2 years, 1:1 randomized,
placebo-controlled trial
▪6979 patients with T2DM




(composite of CV death, MI,
or ischaemic stroke)
No effect on HF-related
endpoints
CAROLINA27 ▪6.3 years, 1:1
randomization vs.
glimepiride
▪6033 patients with T2DM




(composite of CV death, MI,
or ischaemic stroke)
No effect on HF-related
endpoints
Vildagliptin VIVIDD26 ▪52 weeks, 1:1 randomized,
placebo-controlled trial
▪254 patients with T2DM
and HFrEF




Glucagon-like peptide 1 receptor agonists
Lixisenatide ELIXA39 ▪25 months, 1:1
randomized,
placebo-controlled trial
▪6068 patients with T2DM
and a recent ACS
Non-inferiority for the
primary outcome of CV
death, MI, stroke, or
hospitalization for unstable
angina
No effect on HF
hospitalization
Exenatide EXSCEL40 ▪3.2 years, 1:1 randomized,
placebo-controlled trial
▪14 752 patients with T2DM
Non-inferiority for the
primary outcome
(composite of CV death, MI,
or stroke)
Reduced risk of all-cause
mortality and HF
hospitalization, although
this was attenuated in
patients with prevalent HF
Liraglutide LEADER44 ▪3.8 years, 1:1 randomized,
placebo-controlled trial
▪9340 patients with T2DM
and high CV risk
Superiority for the primary
outcome (composite of CV
death, MI, or stroke)
No effect on HF-related
endpoints
FIGHT47 ▪180 days, 1:1 randomized,
placebo-controlled trial
▪300 patients with HFrEF
and a recent hospitalization
No difference in time to death, time to HF hospitalization, and
time-averaged proportional change in NTproBNP
LIVE48 ▪24 weeks, 1:1 randomized,
placebo-controlled trial
▪241 patients with stable
HFrEF
No difference in change in
ejection fraction
Significant increase in heart
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concerns affecting enrolment and the ability to complete the
trial.93
Implications for clinical practice
According to the 2019 ESC guidelines on diabetes, SGLT2i are
recommended (class I; level A) as a first-line therapy for
T2DM in patients with established CV disease, such as those
with HF, either alone or in combination with metformin.28,94
In agreement, the consensus report update from the Ameri-
can Diabetes Association and European Association for the
Study of Diabetes specifically recommends the use of SGLT2i
in patients with T2DM and HF.95 While TZD and the DPP4i
saxagliptin are clearly not recommended in HF because of
the associated increased risk of HF hospitalization (class III;
level A), GLP1-RA (class IIb; level A) and the DPP4i sitagliptin
Table 1 (continued)




▪3297 patients with T2DM
Superiority for the primary
outcome (composite of CV
death, MI, or stroke)
No effect on HF-related
endpoints
PIONEER-645 ▪1.3 years, 1:1 randomized,
placebo-controlled trial




(composite of CV death, MI,
or ischaemic stroke)




▪1.5 years, 1:1 randomized,
placebo-controlled trial
▪9463 patients with T2DM
and CV disease
Superiority for the primary
outcome (composite of CV,
MI, or stroke)
No effect on HF-related
endpoints
Biguanide
Metformin UKPDS 8052 ▪10 years, 1:1 randomized
controlled trial
▪4209 T2DM patients
Reduction of any diabtes-related endpoint including also HF






▪7020 patients with T2DM
and CV disease
Reduction in the primary
outcome (composite of CV
death, MI, or stroke)
Reduced risk of HF
hospitalization irrespective
of baseline HF status
EMPERIAL
reduced87
▪12 weeks, 1:1 randomized,
placebo-controlled trial
▪300 patients with HFrEF
No effect on exercise ability
EMPERIAL
preserved87
▪12 weeks, 1:1 randomized,
placebo-controlled trial
▪300 patients with HFpEF




▪30 days, 1:1 randomized,
placebo-controlled trial
▪80 patients with acute HF
No improvement in dyspnoea, diuretic response, natriuretic
peptide levels, or length of hospital stay, but no safety
concerns and reduction of a combined endpoint of worsening
HF, HF rehospitalization, or death at 60 days
Canagliflozin CANVAS74 ▪188 weeks, 1:1
randomized,
placebo-controlled trial
▪10 142 patients with T2DM
and high CV risk
Superiority for the primary
outcome (composite of CV
death, MI, or stroke)
Reduced risk of HF
hospitalization, possibly
more pronounced in
patients with prevalent HF
Dapagliflozin DECLARE TIMI
5880
▪4.2 years, 1:1 randomized,
placebo-controlled trial
▪17 160 patients with T2DM




(composite of CV death, MI,
or stroke)
Reduced risk of HF
hospitalization, reduced
risk of death in patients
with HFrEF
DAPA-HF83 ▪18 months, 1:1
randomized,
placebo-controlled trial
▪4744 patients with HFrEF
Reduction in the primary composite outcome of CV death and
worsening of HF






Improvement in HF related health status or natriuretic
peptides, but no reduction of mean natriuretic peptide levels
ACS, acute coronary syndrome; CV, cardiovascular; HF, heart failure; HFpEF: heart failure with preserved ejection fraction; HFrEF: heart fail-
ure with reduced ejection fraction; MI, myocardial infarction; T2DM, type 2 diabetes mellitus.
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Table 2 Upcoming trials of antidiabetic therapies focusing heart failure patients
Drug Clinical trial Design Primary endpoint
Empagliflozin EMBRACE HF (NCT03030222) ▪12 week 1:1 randomized,
placebo-controlled trial
▪60 symptomatic HF patients with
implanted PAP monitor
Change in PAP
EMPEROR reduced (NCT03057977) ▪38 month 1:1 randomized,
placebo-controlled trial
▪ 2850 symptomatic HFrEF patients
Composite of time to first
adjudicated CV death of HHF
EMPEROR preserved (NCT03057951) ▪38 month 1:1 randomized,
placebo-controlled trial
▪6000 symptomatic HFpEF patients
with recent structural heart disease
or HHF
Composite of time to first
adjudicated CV death of HHF
EMPA-VISION (NCT03332212) ▪12 week 1:1 randomized,
placebo-controlled trial
▪86 symptomatic HFrEF and HFpEF
patients
Change in phosphocreatine-ATP-
ratio by MR spectroscopy
RECEDE-CHF (NCT03226457) ▪6 week 1:1 randomized, cross-over,
placebo-controlled trial
▪34 symptomatic HF patients with
established diagnosis of T2DM
Change in urine output
ERA-HF (NCT03271879) ▪6 month 1:1 randomized, cross-
over, placebo-controlled trial
▪128 HFrEF patients with ICD/CRT,
established diagnosis of T2DM and
at high risk of arrhythmic events
Burden of premature ventricular
complexes (defined as the
percentage of all betas in a
pre-specified period captured on
ICD/CRT)
Borisov et al. (NCT03753087) ▪38 month 1:1 randomized,
placebo-controlled trial
▪100 symptomatic HFpEF patients
with established diagnosis of T2DM
Change in exercise capacity
measured by 6MWT
SUGAR (NCT03485092) ▪40 weeks 1:1 randomized,
placebo-controlled trial
▪130 symptomatic HFrEF patients
with stablished diagnosis of T2DM
Left ventricular end systolic volume
index and global longitudinal strain
by MR imaging
EMMY (NCT03087773) ▪26 weeks 1:1 randomized,
placebo-controlled trial
▪476 patients with a recent
myocardial infarction and significant
myocardial necrosis
Change in NTproBNP
EMPA-TROPISM (NCT03485222) ▪26 weeks 1:1 randomized,
placebo-controlled trial
▪80 patients with symptomatic
HFmrEF or HFrEF
Left ventricular end systolic volume
and end diastolic volume
Dapagliflozin PRESERVED-HF (NCT03030235) ▪12 weeks 1:1 randomized,
placebo-controlled trial
▪320 patients with symptomatic
HFpEF with recent evidence of
worsening HF
Change in NTproBNP
DEFINE-HF (NCT02653482) ▪12 weeks 1:1 randomized,
placebo-controlled trial
▪263 patients with symptomatic
HFrEF
Change in NTproBNP and change in
HF specific quality of life
questionnaire
DELIVER (NCT03619213) ▪33 months 1:1 randomized,
placebo-controlled trial
▪4700 patients with symptomatic
HFpEF
Composite of CV death, HHF or
urgent HF visit
DETERMINE preserved (NCT03877224) ▪16 week 1:1 randomized,
placebo-controlled trial
▪400 patients with symptomatic
HFpEF
Change in exercise capacity
measured by 6MWT
DETERMINE reduced (NCT03877237) ▪16 week 1:1 randomized,
placebo-controlled trial
▪300 patients with symptomatic
HFrEF
Change in exercise capacity
measured by 6MWT
Asaad et al. (NCT03794518) ▪3 year 1:1 randomized,
placebo-controlled trial
Time to first HHF
(Continues)
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and linagliptin (class IIb; level B) may be considered for T2DM
treatment in HF patients even though these treatments have
not been shown to reduce the risk of HF outcomes.28 Metfor-
min, based on the above-discussed potential beneficial effect
in HF, should be considered for T2DM treatment in HF pa-
tients with estimated glomerular filtration rate > 30 mL/
min/1.73m2.28
In HF patients with an established, non-TZD/saxagliptin
based antihyperglycaemic therapy and with good glycaemic
control, current ESC guidelines recommend to add a
SGLT2i-based regimen to counteract worsening HF.28
Dapagliflozin is the only SGLT2i, which, up to date, has been
shown to be effective in HF without T2DM. Use of SGLT2i as
HF treatment, that is, regardless of T2DM status, is not consid-
ered yet in either American or European guidelines and does
not yet have a regulatory label. Ongoing trials will add to the
evidence in HFrEF and will show whether the effect shown
by dapagliflozin in HFrEF will also hold true in HFpEF.
At present, it is possible to advocate a class effect for
SGLT2i for the prevention of HF in patients with T2DM while
only dapagliflozin should be considered for the treatment of
HF regardless of the presence of T2DM.
SGLT2i are well tolerated, and in general, side effects of
this drug class are genital and urinary tract infections. How-
ever, increased urinary tract infections were not demon-
strated with dapagliflozin in DAPA-HF. SGLT2i can also cause
polyuria with volume depletion.94 Whether the combination
of SGLT2i and sacubitril/valsartan might lead to excessive
diuresis/hypotension represents a current gap in the evi-
dence according to the guidelines and deserves further
investigation.28 The combination of dapagliflozin and
sacubitril/valsartan was well tolerated in DAPA-HF and no in-
creased risk of hypotension leading to discontinuation of ei-
ther drug was observed, although the subsample of subjects
receiving both medications was relatively small. Additionally,
in a recent post hoc analysis of the DAPA-HF trial, the benefit
of dapagliflozin was consistent regardless of background HF
therapy, including sacubitril/valsartan.96 Concomitant di-
uretic therapy, however, should be carefully monitored and,
if needed, reduced upon initiation of SGLT2i or initiation or
uptitration of sacubitril/valsartan. These issues might be of
particular importance in patients with pre-existing chronic
kidney disease and in older patients, who might be more sen-
sitive to shifts in volume status. Finally, more severe compli-
cations such as diabetic keto acidosis or Fournier’s gangrene
(the latter only seen with canagliflozin) are rare but should
be kept in mind.94 Additionally, diabetic keto acidosis was
not increased by dapagliflozin in diabetic and non-diabetic
HF patients in DAPA-HF (Tables 1 and 2).
Conclusions
The interplay and mutual risk increase in T2DM and HF high-
light the need to identify antihyperglycaemic agents able to
prevent HF in T2DM patients and to improve
mortality/morbidity in those with T2DM and established HF.
Current evidence supports the use of SGLT2i as primary treat-
ment for T2DM in patients with and at high risk of HF. At pres-
ent, dapagliflozin has shown benefit for the treatment of
diabetic and non-diabetic patients with HFrEF. Should the tri-
als with the other SGLT2i replicate the results of DAPA-HF,
these agents may receive an HF indication as a class.
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Drug Clinical trial Design Primary endpoint
▪648 patients with HFrEF, a recent
HHF and established diagnosis of
T2DM
Ertugliflozin ERTU-GLS (NCT03717194) ▪24 week 1:1 randomized,
placebo-controlled trial
▪120 patients with stage B HF and
established diagnosis of T2DM
Change in global longitudinal strain
Sotagliflozin SOLOIST-WHF (NCT03521934) ▪32 months 1:1 randomized,
placebo-controlled trial
▪4000 HFrEF patients with
established diagnosis of T2DM who
are hospitalized for HF
Composite of CV death of HHF
Metformin DANHEART (NCT03514108) ▪60 months, 1:1 randomized trial of
metformin vs. placebo
▪1500 symptomatic HFrEF patients
with or at risk of T2DM
Composite of all-cause death, HHF,
acute myocardial infarction or stroke
6MWT, 6-min walk test; CRT, cardiac resynchronization therapy; CV, cardiovascular; HF, heart failure; HFpEF, heart failure with preserved
ejection fraction; HFrEF, heart failure with reduced ejection fraction; HHF, hospitalization for heart failure; ICD, implantable cardioverter
defibrillator; MR, magnetic resonance; PAP, pulmonary artery pressure; T2DM, type 2 diabetes mellitus.
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